马骏，中国科学院院士，中山大学肿瘤防治中心常务副院长、国务院学位委员会第八届学科评议组（特种医学组）召集人、第八届教育部科学技术委员会生命医学部委员、中国临床肿瘤学会（CSCO）鼻咽癌专家委员会主任委员、中国抗癌协会（CACA）鼻咽癌专业委员会主任委员、广东省医学会放射肿瘤学分会主任委员、中国-美国临床肿瘤协会（CSCO-ASCO）鼻咽癌临床诊治指南委员会联合主席。
马骏教授是我国具有重要国际影响力的鼻咽癌诊治专家和研究型医生。依托华南恶性肿瘤防治全国重点实验室平台，38年来，他聚焦高发于我国的鼻咽癌（占全球病例47%），针对全身微小转移灶是引起鼻咽癌转移复发的根源，开展甄别与清除全身微小转移灶的系列研究，提出了“吉西他滨联合顺铂（GP）全身化学治疗（化疗）可重塑以B细胞为核心的抗肿瘤免疫，有效清除全身微小转移灶”的 “增效”理论，制定了“先GP全身化疗，后局部放射治疗（放疗）”的新策略，大幅提高了晚期鼻咽癌患者的生存率；同时，提出“采用临床分期联合miRNA分子标签，甄别出极少发生微小转移灶的低危患者，可降低治疗强度”的“减毒”理论，制定了“豁免化疗及缩小放疗范围”的新方案，显著减少化疗、放疗的毒副反应，改善了生活质量。
1998年至今，美国的鼻咽癌指南（NCCN）中诊疗路径和美国癌症联合会/国际抗癌联盟（AJCC/UICC）分期标准分别进行了6项和9项重大调整，其中各有5项是基于马骏团队的的研究成果，实现了国际鼻咽癌的诊断和治疗由“美国方案”向“中国方案”的跨越。马骏作为最后/唯一通讯作者在国际医学顶尖刊物如N Engl J Med、Lancet（2篇）、JAMA、BMJ（2篇）、Nat Med、Lancet Oncol（5篇）、J Clin Oncol等发表论文140余篇，其中14篇IF > 50，总正面他引6900余次，14篇入选ESI 1%高被引论文，2篇入选1‰热点论文。
马骏教授受美国临床肿瘤协会（ASCO）邀请，作为主席牵头制定了《中国-美国临床肿瘤学会鼻咽癌临床诊治国际指南》（J Clin Oncol，2021，高被引），指导了全球的临床实践；该指南系肿瘤领域首部由中国学者和学术组织领衔制定的国际指南。同时，他受邀为《Lancet》撰写Seminar（Lancet，2019，正文共17页，热点论文），向全球全科医生介绍鼻咽癌的诊疗规范及进展；这是该杂志创刊近200年来首次由中国大陆学者主导完成的以特定疾病为主题的专题研讨。马骏教授迄今已获得2项国家自然科学基金重点项目资助（2012、2019年）。
以中山大学肿瘤防治中心为独立完成单位，第一完成人马骏教授领衔的“基于现代影像技术的鼻咽癌综合治疗研究（2009）”和“鼻咽癌诊疗关键策略研究与应用（2015）”均获国家科学进步二等奖，其相应成果荣获“中国高等学校十大科技进展”2项（2012、2019）、“中国科协中国生命科学十大进展”2项（2020、2021）、“中国医学科学院中国医学重大进展”2项（2020、2022）、“中华医学科技一等奖”3项（2007、2014、2022），马骏教授本人荣获何梁何利基金科学与技术进步奖（2022）、谈家桢临床医学奖（2023）、吴阶平医药创新奖（2020）、及首届全国创新争先奖状（2015）等，并获得全国优秀科技工作者、广东省“突出贡献奖（2018）” 、“南粤创新团队奖（2017）” 、及广东省劳模和工匠人才创新工作室等荣誉称号。马骏教授在2018年获评美国临床肿瘤学会（ASCO）全体大会评审委员，是唯一来自亚洲的学者。
马骏教授是国家“万人计划”领军人才、美国中华医学基金会杰出教授、获评“国之名医·卓越建树”等。他是国家外专局/教育部“创新引智基地（111计划）”项目负责人，作为大会主席连续主办7届（2018~2023年）国际头颈肿瘤研讨会，应邀在国外肿瘤学大会做报告20次。他受邀主编首部英文专著《Nasopharyngeal Cancer - A Practical Guide on Diagnosis and Treatment》（Springer出版，2021），15项研究结果写入了世界通用的放射治疗权威教科书。他指导的多名研究生获得国家高层次人才如长江特聘（2人）、杰青（1人）和优青（1人）；他所率领的团队先后获评“科技部重点领域创新团队”及“教育部创新团队”。中山大学肿瘤医院是世界最大的鼻咽癌治疗中心，在欧洲机构“Expertscape”全球鼻咽癌学术排名中名列第一，马骏为此做出了重要科学贡献。
分管教学（含招生）、预防医学工作。分管部门：科教处（教学与研究生科、毕业后与继续教育科、临床技能培训中心）、肿瘤预防研究科。
代表性论著
（注：# 第一作者；* 通讯作者）
1. Chen YP#, Liu X#, Zhou Q#, Yang KY#, Jin F#, Zhu XD#, Shi M#, Hu GQ#, Hu WH#, Sun Y, Wu HF, Wu H, Lin Q, Wang H, Tian Y, Zhang N, Wang XC, Shen LF, Liu ZZ, Huang J, Luo XL, Li L, Zang J, Mei Q, Zheng BM, Yue D, Xu J, Wu SG, Shi YX, Mao YP, Chen L, Li WF, Zhou GQ, Sun R, Guo R, Zhang Y, Xu C, Lv JW, Guo Y, Feng HX, Tang LL*, Xie FY*, Sun Y*, Ma J*. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 2021 Jul 24;398(10297):303-313. (IF 168.9)
2. Chen YP#, Chan AT, Le QT, Blanchard P, Sun Y*, Ma J*. Nasopharyngeal carcinoma. Lancet. 2019; 394(10192): 64-80. (IF 168.9)
3. Zhang Y#, Chen L#, Hu GQ#, Zhang N#, Zhu XD#, Yang KY#, Jin F#, Shi M#, Chen YP#, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK*, Xie FY*, Sun Y*, Ma J*. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine. 2019; 381(12): 1124-1135. (IF 158.5)
4. Lv JW#, Wei Y#, Yin JH#, Chen YP#, Zhou GQ#, Wei C#, Liang XY#, Zhang Y#, Zhang CJ, He SW, He QM, Huang ZL, Guan JL, Shen JY, Li XM, Li JY, Li WF, Tang LL, Mao YP, Guo R, Sun R, Zheng YH, Zhou WW, Xiong KX, Wang SQ, Jin X, Liu N*, Li GB*, Kuang DM*, Sun Y*, Ma J*. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat Med. 2023 Jun;29(6):1424-1436. (IF 82.9)
5. Tang LL#, Guo R#, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y*, Ma J*. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022 Aug 23;328(8):728-736. (IF 120.7)
6. Mao YP#*, Wang SX#, Gao TS#, Zhang N#, Liang XY#, Xie FY#, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL*, Chen L*, Sun Y*, Ma J*. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023 Feb 6;380:e072133. (IF 105.7)
7. Xu C#, Chen YP#, Du XJ#, Liu JQ#, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J*. Comparative safety of immune checkpoint inhibitors in cancer: a systematic review and network meta-analysis. BMJ. 2018;363:k4226. (IF 105.7)
8. Chen YP, Ismaila N, Chua MLK, Colevas AD, Haddad R, Huang SH, Wee JTS, Whitley AC, Yi JL, Yom SS, Chan ATC, Hu CS, Lang JY, Le QT, Lee AWM, Lee N, Lin JC, Ma B, Morgan TJ, Shah J, Sun Y*, Ma J*. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021 Mar 1;39(7):840-859. (IF 45.3)
9. Ma J#*, Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY, Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma, J Clin Oncol. 2001; 19(5): 1350-1357. (IF 45.3)
10. Tang LL#*, Huang CL#, Zhang N#, Jiang W#, Wu YS#, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L*, Zhou GQ*, Ma J*. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022 Apr;23(4):479-490. (IF 51.1)
11. Tang XR#, Li YQ#, Liang SB#, Jiang W#, Liu F#, Ge WX, Tang LL, Mao YP, He QM, Yang XJ, Zhang Y, Wen X, Zhang J, Wang YQ, Zhang PP, Sun Y, Yun JP, Zeng J, Li L, Liu LZ, Liu N*, Ma J*. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382-393. (IF 51.1)
12. Sun Y#, Li WF#, Chen NY#, Zhang N#, Hu GQ#, Xie FY#, Sun Y#, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J*. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11):1509-1520. (IF 51.1)
13. Liu N#, Chen NY#, Cui RX#, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY*, Ma J*. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13(6):633-41. (IF 51.1)
14. Chen L#, Hu CS#, Chen XZ#, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J*. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13(2):163-71. (IF 51.1)
15. Chen YP#, Wang YQ#, Lv JW#, Li YQ#, Chua M, Le QT, Lee N, Colevas AD, Seiwert T, Hayes D, Riaz N, Vermorken J, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N*, Ma J*. Identification and Validation of Novel Microenvironment-based Immune Molecular Subgroups of Head and Neck Squamous Cell Carcinoma: Implications for Immunotherapy. Ann Oncol. 2019;30:68-75. (IF 50.5)
16. Chen YP#, Wang ZX#, Chen L#, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J*. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2015; 26(1):205-11. (IF 50.5)
17. Chen YP#, Yin JH#, Li WF#, Li HJ#, Chen DP#, Zhang CJ#, Lv JW, Wang YQ, Li XM, Li JY, Zhang PP, Li YQ, He QM, Yang XJ, Lei Y, Tang LL, Zhou GQ, Mao YP, Wei C, Xiong KX, Zhang HB, Zhu SD, Hou Y, Sun Y, Dean M, Amit I, Wu K*, Kuang DM*, Li GB*, Liu N*, Ma J*. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020 Nov;30(11):1024-1042. (IF 44.1)
18. Zhang P#, He Q#, Wang Y#, Zhou G, Chen Y, Tang L, Zhang Y, Hong X, Mao Y, He Q, Yang X, Liu N*, Ma J*. Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma. Signal Transduct Target Ther. 2022 Feb 16;7(1):46. (IF 39.3)
19. Liu N#, He QM#, Chen JW#, Li YQ, Xu YF, Ren XY, Sun Y, Mai HQ, Shao JY, Jia WH, Kang TB, Zeng MS, Ma J*. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth. Mol Cancer. 2014; 13:111. (IF 37.3)
20. Liu N#, Jiang N#, Guo R#, Jiang W, He QM, Xu YF, Li YQ, Tang LL, Mao YP, Sun Y, Ma J*. MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer. 2013; 12(1):123. (IF 37.3)
21. Chen YP#, Lv JW#, Mao YP#, Li XM#, Li JY#, Wang YQ#, Xu C, Li YQ, He QM, Yang XJ, Lei Y, Shen JY, Tang LL, Chen L, Zhou GQ, Li WF, Du XJ, Guo R, Liu X, Zhang Y, Zeng J, Yun JP, Sun Y*, Liu N*, Ma J*. Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses. Mol Cancer. 2021 Jan 11;20(1):14. (IF 37.3)
22. Liu X#, Zhang Y#, Tang LL#, Le QT, Chua ML, Wee JT, Lee NY, O’Sullivan B, Lee AW, Sun Y, Ma J*. Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncol. 2018; 4(8): 1073-1079. (IF 28.4)
23. Liu X#, Chen YP, Li WF, Sun Y, Guo Y, Eisbruch A, Ma J*. Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. JAMA Oncol. 2017; 3(3):414-416. (IF 28.4)
24. Tang LL#, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J*. Prognostic value and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: a study of 924 cases with MR imaging. Radiology. 2010; 257(1):151-7. (IF 19.7)
25. Tang LL#, Chen YP#, Mao YP#, Wang ZX#, Guo R, Chen L, Tian L, Lin AH, Li L, Sun Y, Ma J*. Validation of the 8th Edition of the UICC/AJCC Staging System for Nasopharyngeal Carcinoma From Endemic Areas in the Intensity-Modulated Radiotherapy Era. J Natl Compr Canc Netw. 2017; 15(7):913-919. (IF 13.4)
26. Chen YP#, Wang YQ#, Li WF#, Chen L, Xu C, Lu TX, Lin AH, Yao JJ, Li YC, Sun Y, Mao YP, Ma J*. Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma. J Natl Compr Canc Netw. 2017; 15(3):336-344. (IF 13.4)
27. Chen YP#, Tang LL#, Yang Q#, Poh SS#, Hui EP#, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM*, Chen MY*, Ma J*. Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials. Clin Cancer Res. 2018; 24(8): 1824-1833. (IF 11.5)
28. Ma J#*, Liu L#, Tang L, Zong J, Lin A, Lu T, Cui N, Cui C, Li L*. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma: prognostic value and staging categories. Clin Cancer Res. 2007; 13(5):1445-52. (IF 11.5)
29. Peng H#, Dong D#, Fang MJ#, Li L#, Tang LL, Chen L, Li WF, Mao YP, Fan W, Liu LZ, Tian L, Lin AH, Sun Y, Tian J*, Ma J*. Prognostic Value of Deep Learning PET/CT-Based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma. Clin Cancer Res. 2019 Jul 15; 25(14): 4271-4279. (IF 11.5)
30. Zhang J#, Wen X#, Liu N, Li YQ, Tang XR, Wang YQ, He QM, Yang XJ, Zhang PP, Ma J*, Sun Y*. Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest. J Exp Clin Cancer Res. 2017; 36(1):147. (IF 12.6)
更新日期：2023年11月22日
